Healthcare: 3 Tough Luck Tumbles – Are They Buys?

Industry Focus - A podcast by The Motley Fool

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

Categories:

Spark Therapeutics, Rite Aid, and Alnylam shares have tumbled following news, but that doesn’t necessarily make all three stocks worth buying. Stocks: ONCE, RAD, ALNY

Visit the podcast's native language site